The author of today’s article notes that, over the past year, biotech stocks have underperformed the market, “a surprising turnaround based on their usual tendency to lead the market.” However, the author further acknowledges that the sector’s underperformance is most likely the result of politics (namely rhetoric surrounding high drug prices) rather than some fundamental change, and that the sector will have both winners and losers. In an attempt to identify potential winners, five biotech stocks are highlighted which are trading at low prices (under $5) and growing earnings. To read about these five stocks, CLICK HERE.